244.71
-2.20 (-0.89%)
| Previous Close | 246.91 |
| Open | 246.55 |
| Volume | 207,375 |
| Avg. Volume (3M) | 292,511 |
| Market Cap | 7,095,983,104 |
| Price / Earnings (TTM) | 36.63 |
| Price / Earnings (Forward) | 47.62 |
| Price / Sales | 21.22 |
| Price / Book | 6.61 |
| 52 Weeks Range | |
| Earnings Date | 3 Nov 2025 |
| Profit Margin | 37.17% |
| Operating Margin (TTM) | 41.03% |
| Diluted EPS (TTM) | 4.18 |
| Quarterly Revenue Growth (YOY) | 94.90% |
| Quarterly Earnings Growth (YOY) | 3,734.00% |
| Total Debt/Equity (MRQ) | 0.98% |
| Current Ratio (MRQ) | 9.65 |
| Operating Cash Flow (TTM) | 138.50 M |
| Levered Free Cash Flow (TTM) | 76.74 M |
| Return on Assets (TTM) | 8.66% |
| Return on Equity (TTM) | 13.90% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Krystal Biotech, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | -3.5 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -0.30 |
|
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 11.88% |
| % Held by Institutions | 104.04% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 371.00 (Citigroup, 51.61%) | Buy |
| 371.00 (Jefferies, 51.61%) | Buy | |
| Median | 320.50 (30.97%) | |
| Low | 284.00 (Guggenheim, 16.06%) | Buy |
| Average | 326.25 (33.32%) | |
| Total | 8 Buy | |
| Avg. Price @ Call | 277.64 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 25 Feb 2026 | 284.00 (16.06%) | Buy | 272.50 |
| Chardan Capital | 18 Feb 2026 | 323.00 (31.99%) | Buy | 283.29 |
| Citigroup | 18 Feb 2026 | 371.00 (51.61%) | Buy | 283.29 |
| 12 Jan 2026 | 336.00 (37.31%) | Buy | 272.13 | |
| Jefferies | 17 Feb 2026 | 371.00 (51.61%) | Buy | 287.84 |
| Goldman Sachs | 02 Feb 2026 | 327.00 (33.63%) | Buy | 282.27 |
| B of A Securities | 22 Jan 2026 | 318.00 (29.95%) | Buy | 289.13 |
| HC Wainwright & Co. | 09 Jan 2026 | 310.00 (26.68%) | Buy | 261.41 |
| TD Cowen | 09 Jan 2026 | 306.00 (25.05%) | Buy | 261.41 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| JANNEY DANIEL | - | 270.67 | -60,161 | -16,134,121 |
| ROSSI DINO A | - | 262.67 | -18,950 | -4,977,597 |
| Aggregate Net Quantity | -79,111 | |||
| Aggregate Net Value ($) | -21,111,717 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 269.07 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| JANNEY DANIEL | Director | 26 Feb 2026 | Automatic sell (-) | 7,741 | 276.36 | 2,139,303 |
| JANNEY DANIEL | Director | 25 Feb 2026 | Automatic sell (-) | 700 | 272.50 | 190,750 |
| JANNEY DANIEL | Director | 24 Feb 2026 | Sell (-) | 37,895 | 266.90 | 10,114,176 |
| JANNEY DANIEL | Director | 24 Feb 2026 | Automatic sell (-) | 13,825 | 266.90 | 3,689,893 |
| JANNEY DANIEL | Director | 24 Feb 2026 | Option execute | 37,895 | - | - |
| ROSSI DINO A | Director | 19 Feb 2026 | Sell (-) | 18,950 | 262.67 | 4,977,597 |
| ROSSI DINO A | Director | 19 Feb 2026 | Option execute | 18,950 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |